Health Condition 1: C719- Malignant neoplasm of brain, unspecified
Conditions
Interventions
None listed
Sponsors
Intramural Fund Tata Memorial Hospital
Eligibility
Inclusion criteria
Inclusion criteria: 1.History of chronic steroid usage for comorbidities prior to blood sampling for assessment of systemic inflammatory markers 2.Any known autoimmune disease or immunodeficiency syndrome 3.Any known coagulopathy or thrombo-embolic disease 4.Any suspected or proven systemic infection 5.Recurrent/progressive glioma 6.Positive (Reactive) for any of the following viral markers â?? HIV, Hepatitis B (by HbsAg detection), Hepatitis C. 7.Refusal for study participation 8.Anticipated non-compliance to therapy and/or follow-up
Exclusion criteria
Exclusion criteria: 1.History of chronic steroid usage for comorbidities prior to blood sampling for assessment of systemic inflammatory markers 2.Any known autoimmune disease or immunodeficiency syndrome 3.Any known coagulopathy or thrombo-embolic disease 4.Any suspected or proven systemic infection 5.Recurrent/progressive glioma 6.Positive (Reactive) for any of the following viral markers â?? HIV, Hepatitis B (by HbsAg detection), Hepatitis C. 7.Refusal for study participation 8.Anticipated non-compliance to therapy and/or follow-up
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in the baseline (pre- surgical) systemic inflammatory markers in patients with GBM (WHO Grade IV) compared to lower-grade glioma. (WHO Grades II-III).Timepoint: Post surgery. | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlation of baseline (pre-surgical) systemic inflammatory markers and change in that state over a course of therapy (surgery and radiochemotherapy) with survival outcomes in patients with newly-diagnosed GBM.To find out optimal cut â?? off values for the systemic inflammatory indices for their use in clinical practice.Timepoint: Baseline ( Pre surgery), Immediate post surgery, Pre radio(chemo)therapy, Post completion of radio(chemo)therapy, Post completion of Adjuvant treatment. | — |
Countries
India
Contacts
Public ContactDr Tejpal Gupta
Tata Memorial Centre, Mumbai
Outcome results
None listed